Darius Ludolfs, Lennart F. V. Spickschen, Stefanie Bredehöft, Verena R. Schulze, Marie Oest, Samila Leon Chaviano, Neus Feliu, Markus Fischer, Marc-André Fortin, John V. Frangioni, Wolfgang Maison
{"title":"Zwitterionic Mn(III)-Tetraphenyl Porphyrins: Water-Soluble MRI Contrast Agents with High Relaxivity","authors":"Darius Ludolfs, Lennart F. V. Spickschen, Stefanie Bredehöft, Verena R. Schulze, Marie Oest, Samila Leon Chaviano, Neus Feliu, Markus Fischer, Marc-André Fortin, John V. Frangioni, Wolfgang Maison","doi":"10.1002/cmdc.70268","DOIUrl":null,"url":null,"abstract":"<p>Manganese-based contrast agents (MBCAs) are promising alternatives to currently used gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). This study describes the synthesis and physicochemical evaluation of two new zwitterionic Mn(III) porphyrin chelates (<b>Mn-8</b> and <b>Mn-9</b>). Both compounds were synthesized <i>via</i> copper-catalyzed azide–alkyne cycloaddition (CuAAC) from an azido-substituted precursor. Both zwitterionic compounds are soluble in water and are remarkably stable to acidic pH and transmetallation under challenging conditions. The complexes have a high <i>T</i><sub>1</sub>-relaxivity, comparable to current clinical high-relaxivity GBCAs like gadopiclenol. In addition, zwitterionic complexes <b>Mn-8</b> and <b>Mn-9</b> have superior relaxivity and improved stability compared to Mn-DPDP (mangafodipir, Teslascan). The favorable properties of both compounds can be attributed to the decoration of the chelator with sulfobetaines or <i>N</i>-oxides. Importantly, chelation of Mn(III) by the porphyrin drastically reduces singlet oxygen generation. <b>Mn-8</b> showed good contrast enhancement in vivo. These compounds are thus strong candidates for the development of next-generation gadolinium-free MRI contrast agents.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 8","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.70268","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.70268","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Manganese-based contrast agents (MBCAs) are promising alternatives to currently used gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). This study describes the synthesis and physicochemical evaluation of two new zwitterionic Mn(III) porphyrin chelates (Mn-8 and Mn-9). Both compounds were synthesized via copper-catalyzed azide–alkyne cycloaddition (CuAAC) from an azido-substituted precursor. Both zwitterionic compounds are soluble in water and are remarkably stable to acidic pH and transmetallation under challenging conditions. The complexes have a high T1-relaxivity, comparable to current clinical high-relaxivity GBCAs like gadopiclenol. In addition, zwitterionic complexes Mn-8 and Mn-9 have superior relaxivity and improved stability compared to Mn-DPDP (mangafodipir, Teslascan). The favorable properties of both compounds can be attributed to the decoration of the chelator with sulfobetaines or N-oxides. Importantly, chelation of Mn(III) by the porphyrin drastically reduces singlet oxygen generation. Mn-8 showed good contrast enhancement in vivo. These compounds are thus strong candidates for the development of next-generation gadolinium-free MRI contrast agents.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.